Baldwin Brothers LLC Cara Therapeutics, Inc. Transaction History

Baldwin Brothers LLC

  • $1.43 Billion
  • Q3 2024

A detailed history of Baldwin Brothers LLC transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Baldwin Brothers LLC holds 500 shares of CARA stock, worth $145. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 3,500 85.71%
Holding current value
$145
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024
SELL
$0.26 - $0.38 $780 - $1,140
-3,000 Reduced 85.71%
500 $0
Q4 2023

Jan 08, 2024
SELL
$0.6 - $1.65 $7,510 - $20,653
-12,517 Reduced 78.15%
3,500 $2,000
Q1 2023

Apr 21, 2023
SELL
$4.89 - $12.27 $7,334 - $18,405
-1,500 Reduced 8.56%
16,017 $78,000
Q4 2022

Jan 27, 2023
SELL
$8.88 - $12.77 $7,192 - $10,343
-810 Reduced 4.42%
17,517 $0
Q1 2022

Apr 13, 2022
BUY
$9.94 - $12.65 $52,950 - $67,386
5,327 Added 40.98%
18,327 $223,000
Q4 2021

Jan 14, 2022
SELL
$11.99 - $18.14 $35,970 - $54,420
-3,000 Reduced 18.75%
13,000 $158,000
Q2 2021

Jul 30, 2021
BUY
$12.38 - $29.19 $8,331 - $19,644
673 Added 4.39%
16,000 $228,000
Q1 2021

Apr 08, 2021
SELL
$15.07 - $21.71 $15,070 - $21,710
-1,000 Reduced 6.12%
15,327 $333,000
Q4 2020

Jan 12, 2021
SELL
$12.72 - $16.16 $8,904 - $11,312
-700 Reduced 4.11%
16,327 $247,000
Q1 2020

Apr 15, 2020
SELL
$9.12 - $17.78 $48,582 - $94,714
-5,327 Reduced 23.83%
17,027 $225,000
Q3 2018

Oct 26, 2018
SELL
$17.57 - $23.95 $17,570 - $23,950
-1,000 Reduced 4.28%
22,354 $535,000
Q3 2017

Oct 26, 2017
BUY
$12.6 - $16.34 $294,260 - $381,604
23,354
23,354 $320,000

Others Institutions Holding CARA

# of Institutions
74
Shares Held
12.8M
Call Options Held
0
Put Options Held
0
View Full List

About Cara Therapeutics, Inc.

CARA Quotes by TradingView
  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $15.6M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Baldwin Brothers LLC Portfolio

Follow Baldwin Brothers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baldwin Brothers LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email